Determining the underlying mechanisms of sustained CD8+ T-cell dysfunction after DAA therapy in HCV+(F4) individuals will identify novel therapeutic add-ons to improve clinical outcomes, particularly in this era of rising rates of HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.